Vaccine trial aims to train immune system to fight leukemia relapse
NCT ID NCT03059485
Summary
This study is testing a cancer vaccine to see if it can help prevent acute myeloid leukemia (AML) from coming back after successful chemotherapy. The vaccine is made by combining a patient's own immune cells with their leukemia cells, aiming to teach the body's immune system to recognize and attack any remaining cancer. The trial will compare patients who receive the vaccine to those who are simply observed after remission, measuring how long they stay cancer-free and their overall survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.